

4th Annual Awardees (2021-2022)

Research Focus: Alcohol Use Disorder

- ▶ **Walter Roberts, Ph.D.**, Yale University
 - Predicting alcohol use events in people with AUD using mobile sensors: towards automated telehealth treatment

Research Focus: Opioid Use Disorder

- ▶ **Amanda Lowell, Ph.D.**, Yale University
 - Neuroplasticity in Maternal Opioid Use Disorder

Research Focus: Schizophrenia

- ▶ **Renato Polimanti, Ph.D., M.Sc.**, Yale University
 - The impact of socioeconomic factors on psychiatric and somatic comorbidities of schizophrenia: a genetically-informed epidemiological study rat model
- ▶ **Kangho Suh, Pharm.D., Ph.D.**, University of Pittsburgh
 - Assessing the comparative and cost-effectiveness of second-generation antipsychotics long-acting injectables in schizophrenia

Research Focus: Bipolar Disorder

- ▶ **Claudia Lopes, Ph.D.**, McLean Hospital, Harvard Medical School
 - Altered Glutamatergic Development in Hippocampal-Cortical Circuitry in 3D models of Psychotic Disorder

3rd Annual Awardees (2020-2021)

Research Focus: Addiction

- ▶ **Jessica Ables, M.D., Ph.D.**, Icahn School of Medicine at Mount Sinai
 - Role of nitric oxide in opioid tolerance
- ▶ **Stephanie Caligiuri, Ph.D.**, Icahn School of Medicine at Mount Sinai
 - Chemosensing in the choroid plexus regulates the addiction-relevant actions of opioids

Research Focus: Bipolar Disorder

- ▶ **Anastasiya Nestsiarovich, M.D., Ph.D.**, The Regents of the University of California; University of California San Diego
 - Stem cell modeling of cryptic bipolar disorder in treatment resistant depression

Research Focus: Schizophrenia

- ▶ **Paulo Lizano, M.D., Ph.D.**, Beth Israel Deaconess Medical Center/Harvard Medical School
 - Proof of mechanism study using a retinal biomarker to predict treatment response with intravenous sodium nitroprusside in symptomatic early course schizophrenia
- ▶ **Summer Thyme, Ph.D.**, The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
 - New algorithms for in silico discovery of small molecule drugs targeting schizophrenia-associated genes

2nd Annual Awardees (2019-2020)

Research Focus: Addiction

- ▶ **Caroline A. Arout, Ph.D.**, Columbia University Irving Medical Center and New York State Psychiatric Institute
 - Effects of repeated high-cannabidiol cannabis administration on experimental pain and abuse liability in humans
- ▶ **Gregory F. Corder, Ph.D.**, University of Pennsylvania
 - Prevention of neurodevelopmental disabilities associated with neonatal opioid withdrawal
- ▶ **Victor Philippe Mathis, Ph.D.**, Icahn School of Medicine at Mount Sinai
 - Defining the role of cortical inputs to the habenula in the control of midbrain dopamine neurons and addiction-related behaviors
- ▶ **Cody A. Siciliano, Ph.D.**, Vanderbilt University
 - Neural mechanisms of cognitive dysfunction and alcohol abuse vulnerability

Research Focus: Schizophrenia

- ▶ **Michael S Breen, Ph.D.**, Icahn School of Medicine at Mount Sinai
 - Functional and translational implications of A-to-I RNA editing in schizophrenia
- ▶ **Xi Chen, Ph.D.**, McLean Hospital, Harvard Medical School
 - In vivo research observing brain lactate changes in first-episode schizophrenia using 3-T magnetic resonance spectroscopy
- ▶ **Amanda McCleery, Ph.D.**, University of California Los Angeles (UCLA) Semel Institute for Neuroscience and Human Behavior
 - Impact of aripiprazole medication adherence on learning and neuroplasticity in recent-onset schizophrenia: A comparison of long-acting injectable and oral formulations
- ▶ **Jose M Rubio, M.D.**, Zucker School of Medicine at Hofstra/Northwell
 - Fluctuations in resting state functional connectivity associated with psychosis relapse during antipsychotic maintenance

1st Annual Awardees (2018)

Research Focus: Addiction

- ▶ **Lais Fernanda Berro, Ph.D.**, University of Mississippi Medical Center
 - Quantitative pharmacology and pharmacotherapeutics for opioid and benzodiazepine coabuse

- ▶ **Mehdi Farokhnia, M.D.**, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
 - Examining the neurobiological correlates and pharmacotherapeutic implications of the GLP-1 system in relation to alcohol use

- ▶ **Sarah L. Withey, Ph.D.**, Harvard Medical School, McLean Hospital
 - Effects of continuous exposure to naltrexone on the behavior and reward circuitry involved in opioid addiction relapses in non-human subjects